Research and Markets: Stakeholder Opinions: Urinary Tract Infections - Ciprofloxacin Leads the Way.

DUBLIN, Ireland -- UTIs Are the Second-Most Common Type of Bacterial Infection, after Those of the Respiratory Tract, with More Than 35 Million Medically Treated Infections across the Seven Major Markets Each Year

Research and Markets (http://www.researchandmarkets.com) has announced the addition of Stakeholder Opinions: Urinary Tract Infections - Ciprofloxacin Leads the Way to their offering.

Urinary tract infections are one of the most common bacterial infections across the seven major markets, second only to respiratory tract infections.

As a result, such infections generate a significant proportion of antibacterial revenue and are the focus of key players and new entrants alike.

Scope of Report:

Commercial overview of the current UTIs antibacterial market in the US, EU and Japan

A description of presentation, diagnostic and treatment practices in selected countries, based on discussions with numerous key opinion leaders

Examination of how the patent expiry of Cipro has impacted this market and how niche products have gained leverage in the UTIs sector

Investigation into why and how antibacterial companies may tailor marketing strategies to the community or hospital setting

Report Highlights:

UTIs are the second-most common type of bacterial infection, after those of the respiratory tract, with more than 35 million medically treated infections across the seven major markets each year. This translated into sales in excess of $1.1billion across key markets in 2003, with the majority of value derived from community management.

The recent US patent expiry of Bayers Cipro will result in the increased availability of cheaper versions of the leading UTI antibacterial. As a result, the recent decline in UTI market value is expected to continue over the next 2-3 years, as physicians switch to generic ciprofloxacin, despite the availability of once-daily Cipro XR.

Community-based physicians across the major markets prescribe antibacterials for UTIs without knowledge of causative pathogens or specific site of infection. As a result, success in the community is driven by broad-spectrum activity, while the role for more specific therapies is currently limited in this sector.

Reasons to Purchase:

--Gain an understanding of current routes of presentation, diagnosis and treatment practices in key economic markets

--Learn about the key antibacterials prescribed for treating UTIs, the strengths and weaknesses of each and unmet needs in treating such infections

--Find out how patent expiry has impacted this sector, and how reformulation strategies may prevent generic incursion 

Report Contents:

Chapter 1 Executive Summary

Chapter 2 Disease Definition and Epidemiology

Chapter 3 Presentation and Diagnosis

Chapter 4 Market Analysis

Chapter 5 Strategic Evaluation

For more information visit http://www.researchandmarkets.com/reports/c4922